Lysbeth Floden1, Douglas L Taren1, Myra L Muramoto2, Scott J Leischow3. 1. College of Public Health, University of Arizona, Tucson, Arizona, USA. 2. Department of Family and Community Medicine, University of Arizona, Tucson, Arizona, USA. 3. Mayo Clinic, Phoenix, Arizona, USA.
Abstract
OBJECTIVE: Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial ofbupropion SR (150 mg/day and 300 mg/day) for smoking cessation. METHODS:A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months. RESULTS: Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up. CONCLUSIONS: A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.
RCT Entities:
OBJECTIVE: Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial of bupropion SR (150 mg/day and 300 mg/day) for smoking cessation. METHODS: A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months. RESULTS: Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up. CONCLUSIONS: A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.
Authors: Nicolaas P Pronk; Louise H Anderson; A Lauren Crain; Brian C Martinson; Patrick J O'Connor; Nancy E Sherwood; Robin R Whitebird Journal: Am J Prev Med Date: 2004-08 Impact factor: 5.043
Authors: Eric T Moolchan; Miqun L Robinson; Monique Ernst; Jean Lud Cadet; Wallace B Pickworth; Stephen J Heishman; Jennifer R Schroeder Journal: Pediatrics Date: 2005-04 Impact factor: 7.124
Authors: J T Hays; R D Hurt; N A Rigotti; R Niaura; D Gonzales; M J Durcan; D P Sachs; T D Wolter; A S Buist; J A Johnston; J D White Journal: Ann Intern Med Date: 2001-09-18 Impact factor: 25.391
Authors: Elissa Thorner-Bantug; Maria Jaszyna-Gasior; Jennifer R Schroeder; Charles C Collins; Eric T Moolchan Journal: J Natl Med Assoc Date: 2009-10 Impact factor: 1.798
Authors: Thomas R Fanshawe; William Halliwell; Nicola Lindson; Paul Aveyard; Jonathan Livingstone-Banks; Jamie Hartmann-Boyce Journal: Cochrane Database Syst Rev Date: 2017-11-17